Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls

Indirect Comparison ◽

Small Cell ◽

Comparative Efficacy ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Adjusted Indirect Comparison

Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8058 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8058-8058

Author(s):

Daniel Shao-Weng Tan ◽

Antonio Araujo ◽

Jie Zhang ◽

James E. Signorovitch ◽

Zheng-Yi Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Indirect Comparison ◽

Small Cell ◽

Comparative Efficacy ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Adjusted Indirect Comparison ◽

Previously Treated

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

PCN1 TOLERABILITY OF FIRST-LINE TREATMENTS OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC):A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON

Value in Health ◽

10.1016/s1098-3015(11)71898-8 ◽

2010 ◽

Vol 13 (7) ◽

pp. A250

Author(s):

SJ Edwards ◽

N Welton ◽

J Borrill

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Indirect Comparison ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Adjusted Indirect Comparison

The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer

Future Oncology ◽

10.2217/fon-2018-0027 ◽

2018 ◽

Vol 14 (18) ◽

pp. 1875-1882 ◽

Cited By ~ 3

Author(s):

Shirish M Gadgeel

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

Translational Oncology ◽

10.1016/j.tranon.2021.101338 ◽

2022 ◽

Vol 17 ◽

pp. 101338

Author(s):

Xinru Chen ◽

Xiangchan Hong ◽

Gang Chen ◽

Jinhui Xue ◽

Jie Huang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Inhibitor ◽

Immune Inflammation

The impact of baseline brain metastases on clinical benefits and progression patterns after first-line crizotinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer

Medicine ◽

10.1097/md.0000000000024784 ◽

2021 ◽

Vol 100 (8) ◽

pp. e24784

Author(s):

Yuqi Chen ◽

Chengzhi Cai ◽

Yanying Li

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Clinical Benefits ◽

The Impact

What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?

Journal of Thoracic Disease ◽

10.21037/jtd.2017.04.43 ◽

2017 ◽

Vol 9 (5) ◽

pp. E447-E450

Author(s):

Ikuo Sekine

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

BMC Cancer ◽

10.1186/s12885-017-3720-8 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 9

Author(s):

Jianya Zhou ◽

Jing Zheng ◽

Xiaochen Zhang ◽

Jing Zhao ◽

Yanping Zhu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer

Clinical Drug Investigation ◽

10.1007/s40261-019-00880-8 ◽

2019 ◽

Vol 40 (2) ◽

pp. 183-189 ◽

Cited By ~ 3

Author(s):

Hongchao Li ◽

Lei Lai ◽

Bin Wu

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma

First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial

10.1055/s-0039-3403360 ◽

2020 ◽

Author(s):

MJ Hochmair ◽

DR Camidge ◽

HR Kim ◽

MJ Ahn ◽

JCH Yang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Anaplastic Lymphoma ◽

First Line Therapy ◽

Line Therapy